SAN FRANCISCO, Oct. 10 - Lexicon Genetics has licensed its gene-targeting isogenic DNA technology to US drug giant Pfizer, the companies announced on Wednesday.

Financial details of the agreement were not disclosed.

The non-exclusive internal research-use license is the second The Woodlands, Texas-based Lexicon has licensed to Pfizer, which also holds a non-exclusive license from Lexicon for internal research use of Lexicon's positive-negative selection technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.